Clinical Trials Logo

Hepatitis C, Chronic clinical trials

View clinical trials related to Hepatitis C, Chronic.

Filter by:

NCT ID: NCT02202980 Completed - Chronic Hepatitis C Clinical Trials

Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection

LEPTON
Start date: August 4, 2014
Phase: Phase 2
Study type: Interventional

This study will evaluate the antiviral efficacy, safety, and tolerability of combination therapy with oral regimens for the treatment of chronic hepatitis C virus (HCV) infection.

NCT ID: NCT02185794 Completed - Clinical trials for Hepatitis C Virus Infection

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

Start date: June 13, 2014
Phase: Phase 1
Study type: Interventional

The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.

NCT ID: NCT02176980 Completed - Clinical trials for Hepatitis C, Chronic; AUD

Hepatitis C Alcohol Reduction Treatment

HepART-RCT
Start date: October 2014
Phase: N/A
Study type: Interventional

Subjects are being asked to take part in a research study to test two levels of alcohol services for patients with hepatitis C virus (HCV) who drink alcohol. The two levels differ in intensity of alcohol services and in whether or not they include a focus on liver health. The study will look at which level of alcohol services best decreases alcohol use among patients with HCV.

NCT ID: NCT02176525 Completed - Clinical trials for Hepatitis C, Chronic

Multiple Oral Doses of BI 207127 NA in Treatment naïve and Treatment-experienced Hepatitis C Virus (HCV)-Infected Patients

Start date: December 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study was to investigate antiviral activity, safety and pharmacokinetics of 5 days of monotherapy with BI 207127 in HCV genotype 1 (GT1) infected patients. Both treatment-naïve patients and patients previously treated with peginterferon and ribavirin were included. In addition, the effect of study medication was examined in a group of patients with liver cirrhosis.

NCT ID: NCT02175966 Completed - Hepatitis C Clinical Trials

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)

FOURward
Start date: July 28, 2014
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether the combination of Daclatasvir (DCV), Asunaprevir (ASV), BMS-791325 and Sofosbuvir is effective and safe in treating Hepatitis-C virus.

NCT ID: NCT02170727 Completed - Hepatitis C Virus Clinical Trials

A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1

UNITY 4
Start date: June 26, 2014
Phase: Phase 3
Study type: Interventional

To demonstrate the effectiveness of Daclatasvir (DCV) 3 Direct Acting Antivirals (DAA) fixed dose combination in Genotype 1 Chronic Hepatitis C subjects.

NCT ID: NCT02168361 Completed - Chronic Hepatitis C Clinical Trials

The SIM-SOF Trial for Hepatitis C

Start date: December 2013
Phase: Phase 4
Study type: Interventional

Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without Ribavirin.

NCT ID: NCT02167945 Completed - Clinical trials for Chronic Hepatitis C Virus (HCV) Infection Genotype 1

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

TOPAZ-II
Start date: June 12, 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic hepatitis C virus genotype 1 (HCV GT1) infection.

NCT ID: NCT02161952 Completed - Fibrosis Clinical Trials

Pirfenidone, an Antifibrotic and Antiinflammatory Drug

Start date: May 2005
Phase: Phase 2
Study type: Interventional

The aim of this study was to assess whether two-year treatment with Pirfenidone influence necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.

NCT ID: NCT02123654 Completed - Clinical trials for Hepatitis C Virus Infection

UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C

Start date: April 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that the proportion of treatment-naive non-cirrhotic subjects with Genotype (GT)-1b treated with Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 who achieve Sustained Virologic response (SVR12), defined as Hepatitis C virus (HCV) RNA < LOQ target detected or target not detected (LOQ TD/TND) at follow-up Week 12, is significantly higher than SVR12 of current Standard of Care (SOC).